- BH CH	envork Reduction Act of 1995, no c ANSMITTAL FORM	persons are required to respond to a coll Application Number Filing Date First Named Inventor Art Unit	(Substitute) PTO-SBIZE for Appropriate uses through DYS/1/2005 ONE 003-1/020 ones and formation unless it discless a valid OMB control number 10/518,244  December 16, 2004  Reddy Bandi Parthasarradhi, et al		
	Pages in This Submission 26	Attorney Docket Number	H1089/20024		
Amendme Af Af Extension Express A V Informatic Certified Decumer Incomplet	ter Final fidevits/declaration(s) of Time Request Lbandonnent Request in Disclosure Statement Copy of Priority (s) desire parties of the Copy of Priority (s) desired parties of the Copy	nsure consideration of this subr	Address Status Letter Other Enclosure(s) (please Identify below): PTO FORM 1449 AND CITED REFERENCES RETURN RECEIPT POSTCARD  No. 03-0075 as necessary to effect entry and/or mission.		
Firm Name		Cohen & Pokotilow Ltd., Cust			
Signature	Caesar, Rivise, Bernstein, Cohen & Pokolilow, Ltd., Customer No. 03000				
Printed name  Date	Robert S. Silver		Reg. No. 35,681		
I hereby certify the sufficient postage the date shown b	nat this correspondence is being as first class mail in an envel	RTIFICATE OF TRANSMISS  Ing facsimile transmitted to the USE  ope addressed to: Commissioner for cosmile.No. (703)	SION/MAILING  For deposited with the United States Postal Service with an Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public white is to fit give by the 19FOTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 11.4. This collection is estimated by 2 Nove is completed including substrainty, prepared, and substrainting the completed applications of the 19FOTO o

21005

Date

Signature

Typed or printed name

Robert S. Silver





Applicant(s): Reddy Bandi Parthasaradhi, et al

Serial No: 10/518,214

Group Art Unit: Examiner:

Filed: December 16, 2004

Att. Docket No.: H1089/20024

Confirmation No.:

For: ARIPIPRAZOLE CRYSTALLINE FORMS

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the reference(s) is/are prior art with respect to this application.

This Information Disclosure Statement is being filed within three months of the filing date of a national application other than a CPA under 37 CFR § 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of an RCE under 37 CFR § 1.114. No certification or fee is required. 37 CFR § 1.97(b).

## Application No. 10/518,214

Regarding JP Unexamined Patent Publication No. 191256, Applicants believe that this publication is equivalent to the disclosure of U. S. Patent No. 5,006,528 (enclosed), which provides the English translation of JP 19125, as required.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.

February 25, 2005

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission. Robert S. Silver
Registration/No. 35,681
Customer/No. 03000
(215) 567-2010
Attorneys for Applicant(s)

U.S. Patent and Trademark Office: U.S. DEPAR
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

se type a plus sign (+) inside this box

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)

Complete if Known
Application Number 10/518,214
Fifting Date December 16, 2004
First Named Inventor Reddy Bandi
Parthasaradhi, et al
Group Art Unit
Examiner Name
Attorney Docket Number H1089/20024

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Cite No.		U.S. Palent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Number	(if known)			
/ES/ /E	S/	5,006,528		Oshiro, et al	

FOREIGN PATENT DOCUMENTS

Examiner Cite Initials* No.	Foreign Patent Document		1	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Ι,	
	Office	Number	(If known)	reging of Pateringe of Applicans of Cited Documents	MM-DD-YYYY	Ė	
/ES/			WO 03/026659		Bando, et al		
/ES/			EP 367 141		Oshiro, et al		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
/ES/		PCT INTERNATIONAL SEARCH REPORT DATED JULY 25, 2003	
/ES/		Japanese Unexamined Patent Publication No. 191256	
/ES/		Satoshi Aoki et al. "Study on Crystal Transformation of Aripiprazol" in the Fourth Japan - Korea Symposium on Separation Technology. The Korean Institute of Chemical Engineers, October 1996, CR 119, pp. 937-940	
			_
			1

EXAMINER /Ebenezer Sackey/ (12/24/2007) DATE CONSIDERED

/Ebenezer Sackey/ (12/24/2007)

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.